{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:50:55Z","timestamp":1790117455143,"version":"4.0.1"},"reference-count":114,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T00:00:00Z","timestamp":1765670400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"\u201cDunarea de Jos\u201d University"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Antiretroviral therapy (ART) effectively suppresses HIV replication but fails to eradicate latent reservoirs, leading to viral rebound after interruption. Chimeric antigen receptor (CAR) T-cell therapy offers a potential strategy to achieve durable remission. A systematic PubMed search (July 2020\u2013June 2025) identified 253 studies on CAR-T therapy in HIV; 74 met inclusion criteria and were qualitatively analyzed. Preclinical data showed that CAR-T cells can recognize and eliminate infected cells, reach viral reservoirs, and persist long term, particularly when derived from hematopoietic stem cells. Dual-target and combination approaches with checkpoint inhibitors or latency-reversing agents enhanced antiviral efficacy. Early clinical studies confirmed safety and modest reservoir reduction. CAR-T cell therapy represents a promising step toward a functional HIV cure. Further optimization of design, integration with gene-editing technologies, and standardized clinical evaluation are required to confirm durable efficacy and safety.<\/jats:p>","DOI":"10.3390\/v17121615","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T09:36:39Z","timestamp":1765791399000},"page":"1615","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["CAR-T Cell Therapy for HIV Cure: Current Challenges, Advances and Future Directions"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4237-2297","authenticated-orcid":false,"given":"Monica-Daniela","family":"Padurariu-Covit","sequence":"first","affiliation":[{"name":"Department of Clinical Medicine, Medicine and Pharmacy Faculty, \u201cDunarea de Jos\u201d University of Galati, 800008 Galati, Romania"},{"name":"Department of Hematology, Emergency County Hospital Sf. Apostol Andrei, 800578 Galati, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costinela","family":"Georgescu","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Medicine and Pharmacy Faculty, \u201cDunarea de Jos\u201d University of Galati, 800008 Galati, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0532-7929","authenticated-orcid":false,"given":"Mihaela","family":"Andreescu","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Titu Maiorescu University, 031593 Bucharest, Romania"},{"name":"Department of Hematology, Colentina Clinical Hospital, 050098 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iulia","family":"Chiscop","sequence":"additional","affiliation":[{"name":"Department of Clinical Surgery, \u201cDunarea de Jos\u201d University of Galati, 800008 Galati, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3111-4089","authenticated-orcid":false,"given":"Catalin","family":"Plesea-Condratovici","sequence":"additional","affiliation":[{"name":"Department of Morphological and Functional Sciences, Faculty of Medicine and Pharmacy, \u201cDunarea de Jos\u201d University of Galati, 800008 Galati, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4762-0755","authenticated-orcid":false,"given":"Manuela","family":"Arbune","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Medicine and Pharmacy Faculty, \u201cDunarea de Jos\u201d University of Galati, 800008 Galati, Romania"},{"name":"Department of Infectious Diseases, Clinic I, Infectious Diseases Clinic Hospital Sf. Cuv. Parascheva, 800179 Galati, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,14]]},"reference":[{"key":"ref_1","unstructured":"UNAIDS (2025, October 07). Global HIV & AIDS Statistics\u2014Fact Sheet 2025. Available online: https:\/\/www.unaids.org\/en\/resources\/fact-sheet."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"101856","DOI":"10.1016\/j.genrep.2023.101856","article-title":"The CCR5\u039432 allele as an HIV infection resistance marker: Possible evolutionary theories of origin","volume":"34","author":"Alfilali","year":"2024","journal-title":"Gene Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1016\/j.bmcl.2013.05.032","article-title":"HIV\/AIDS eradication","volume":"23","author":"Marsden","year":"2013","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/jleuko\/qiac007","article-title":"Mapping the interplay between NK cells and HIV: Therapeutic implications","volume":"113","author":"Anderko","year":"2023","journal-title":"J. Leukoc. Biol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1056\/NEJMoa0903175","article-title":"Interleukin-2 therapy in patients with HIV infection","volume":"361","author":"Abrams","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1056\/NEJM199610313351803","article-title":"Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus","volume":"335","author":"Kovacs","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"13193","DOI":"10.1073\/pnas.94.24.13193","article-title":"Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy","volume":"94","author":"Chun","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/nature20583","article-title":"Ad26\/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys","volume":"540","author":"Borducchi","year":"2016","journal-title":"Nature"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nature14411","article-title":"3BNC117, a Broadly Neutralizing Antibody, Suppresses Viremia in HIV-1-Infected Humans","volume":"522","author":"Caskey","year":"2015","journal-title":"Nature"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ebiom.2019.06.020","article-title":"Deep latency: A new insight into a functional HIV cure","volume":"45","author":"Elsheikh","year":"2019","journal-title":"eBioMedicine"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1038\/s41591-021-01590-5","article-title":"Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021","volume":"27","author":"Deeks","year":"2021","journal-title":"Nat. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12977-024-00655-w","article-title":"Exploring potential associations between the human microbiota and reservoir of latent HIV","volume":"21","author":"Paredes","year":"2024","journal-title":"Retrovirology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e161698","DOI":"10.1172\/jci.insight.161698","article-title":"In vivo killing of primary HIV-infected cells by peripheral-injected early memory\u2013enriched anti-HIV duoCAR T cells","volume":"7","author":"Ray","year":"2022","journal-title":"JCI Insight"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Campos-Gonzalez, G., Martinez-Picado, J., Velasco-Hernandez, T., and Salgado, M. (2023). Opportunities for CAR-T cell immunotherapy in HIV cure. Viruses, 15.","DOI":"10.3390\/v15030789"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41421-024-00658-z","article-title":"Efficacy and safety of novel multifunctional M10 CAR-T cells in HIV-1-infected patients: A phase I, multicenter, single-arm, open-label study","volume":"10","author":"Mao","year":"2024","journal-title":"Cell Discov."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: What we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.omtn.2023.03.018","article-title":"Lentiviral vectors for inducible, transactivator-free advanced therapy medicinal products: Application to CAR-T cells","volume":"32","author":"Pavlovic","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Loos, P., Short, L., Savage, G., and Evgin, L. (2023). Expansion and retroviral transduction of primary murine T cells for CAR T-cell therapy. Cancer Immunotherapy: Methods and Protocols, Springer.","DOI":"10.1007\/978-1-0716-3593-3_4"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Rossi, M., and Breman, E. (2024). Engineering strategies to safely drive CAR T-cells into the future. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1411393"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Xiao, Q., He, S., Wang, C., Zhou, Y., Zeng, C., Liu, J., Liu, T., Li, T., Quan, X., and Wang, L. (2025). Deep Thought on the HIV Cured Cases: Where Have We Been and What Lies Ahead?. Biomolecules, 15.","DOI":"10.3390\/biom15030378"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJMoa0802905","article-title":"Long-term control of HIV by CCR5\u039432\/\u039432 stem-cell transplantation","volume":"360","author":"Nowak","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1056\/NEJMc1412279","article-title":"More on shift of HIV tropism in stem-cell transplantation with CCR5\u039432\/\u039432 mutation","volume":"371","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2010-09-309591","article-title":"Evidence for the cure of HIV infection by CCR5\u039432\/\u039432 stem cell transplantation","volume":"117","author":"Allers","year":"2011","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S1473-3099(17)30702-8","article-title":"HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: A systematic review and meta-regression analysis","volume":"18","author":"Gupta","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41591-023-02213-x","article-title":"In-depth virological and immunological characterization of HIV-1 cure after CCR5\u039432\/\u039432 allogeneic hematopoietic stem cell transplantation","volume":"29","author":"Jensen","year":"2023","journal-title":"Nat. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJMc2312556","article-title":"HIV-1 remission after allogeneic hematopoietic-cell transplantation","volume":"390","author":"Dickter","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.cell.2023.02.030","article-title":"HIV-1 remission and possible cure in a woman after haplo-cord blood transplant","volume":"186","author":"Hsu","year":"2023","journal-title":"Cell"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1038\/s41591-024-03277-z","article-title":"Sustained HIV remission after allogeneic hematopoietic stem cell transplantation with wild-type CCR5 donor cells","volume":"30","author":"Mamez","year":"2024","journal-title":"Nat. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/d41586-024-02463-w","article-title":"Seventh patient \u2018cured\u2019 of HIV: Why scientists are excited","volume":"632","author":"Mallapaty","year":"2024","journal-title":"Nature"},{"key":"ref_30","unstructured":"Zaegel-Faucher, O., Boschi, C., Benkouiten, S., Laroche, H., Dos Santos, M.C., Motte, A., Izadifar-Legrand, F., Olive, D., Colson, P., and Bregigeon-Ronot, S. (2024, January 10\u201313). Absence of Viral Rebound without Antiretrovirals after CCR5\u039432\/\u039432 Allogeneic Hematopoietic Stem Cell Transplantation: A New Case of a Potential Cure of HIV?. Proceedings of the HIV Drug Therapy Conference, Barcelona, Spain."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"100670","DOI":"10.1016\/j.medj.2025.100670","article-title":"A genetic fingerprint associated with durable HIV remission after interruption of antiretroviral treatment: ANRS VISCONTI\/PRIMO","volume":"6","author":"Essat","year":"2025","journal-title":"Med"},{"key":"ref_32","first-page":"1941","article-title":"The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment controllers identified from 14 clinical studies","volume":"219","author":"Li","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Shacklett, B.L., Buggert, M., and Dias, J. (2023). Editorial: CD8+ T-cells in HIV\/SIV infection, prophylaxis, and therapy. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1159452"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/ID9.0000000000000129","article-title":"CAR-T Therapy in HIV: Pioneering Advances and Navigating Challenges","volume":"4","author":"Wang","year":"2024","journal-title":"J. Infect. Dis. Immun."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Bjorgen, J.C., Dick, J.K., Cromarty, R., Hart, G.T., and Rhein, J. (2023). NK cell subsets and dysfunction during viral infection: A new avenue for therapeutics?. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1267774"},{"key":"ref_36","first-page":"54","article-title":"Addressing graft-versus-host disease in allogeneic cell-based immunotherapy","volume":"14","author":"Kheiri","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/JLB.5RU0821-412RR","article-title":"NK cell-based therapies for HIV infection: Investigating current advances and future possibilities","volume":"111","year":"2022","journal-title":"J. Leukoc. Biol."},{"key":"ref_38","unstructured":"(2025, October 07). PROSPERO International Prospective Register of Systematic Reviews. Available online: https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD42041178068."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: A Tool for Assessing Risk of Bias in Non-Randomised Studies of Interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A Revised Tool for Assessing Risk of Bias in Randomised Trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Mu, W., Carrillo, M.A., and Kitchen, S.G. (2020). Engineering CAR T Cells to Target the HIV Reservoir. Front. Cell. Infect. Microbiol., 10.","DOI":"10.3389\/fcimb.2020.00410"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Matsui, Y., and Miura, Y. (2024). Advancements in cell-based therapies for HIV cure. Cells, 13.","DOI":"10.3390\/cells13010064"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/COH.0000000000000858","article-title":"Recent advances on anti-HIV CAR-T cell treatment to provide sustained HIV remission","volume":"19","author":"Su","year":"2024","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Buck, A.M., Deveau, T.-M., Henrich, T.J., and Deitchman, A.N. (2023). Challenges in HIV-1 Latent Reservoir and Target Cell Quantification in CAR-T Cell and Other Lentiviral Gene Modifying HIV Cure Strategies. Viruses, 15.","DOI":"10.3390\/v15051126"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Borrajo, A. (2025). Breaking Barriers to an HIV-1 Cure: Innovations in Gene Editing, Immune Modulation, and Reservoir Eradication. Life, 15.","DOI":"10.3390\/life15020276"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Kruglova, N., and Shepelev, M. (2024). Increasing Gene Editing Efficiency via CRISPR\/Cas9- or Cas12a-Mediated Knock-In in Primary Human T Cells. Biomedicines, 12.","DOI":"10.3390\/biomedicines12010119"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Rothemejer, F.H., Lauritsen, N.P., Juhl, A.K., Schleimann, M.H., K\u00f6nig, S., S\u00f8gaard, O.S., Bak, R.O., and Tolstrup, M. (2023). Development of HIV-Resistant CAR T Cells by CRISPR\/Cas-Mediated CAR Integration into the CCR5 Locus. Viruses, 15.","DOI":"10.3390\/v15010202"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1097\/CM9.0000000000002904","article-title":"Targeting the HIV reservoir: Chimeric antigen receptor therapy for HIV cure","volume":"136","author":"Li","year":"2023","journal-title":"Chin. Med. J."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"113395","DOI":"10.1016\/j.biopha.2022.113395","article-title":"CD38: An important regulator of T cell function","volume":"153","author":"Li","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"York, J., Gowrishankar, K., Micklethwaite, K., Palmer, S., Cunningham, A.L., and Nasr, N. (2022). Evolving strategies to eliminate the CD4 T cells HIV viral reservoir via CAR T cell immunotherapy. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.873701"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"100965","DOI":"10.1016\/j.blre.2022.100965","article-title":"One arrow for two targets: Potential co-treatment regimens for lymphoma and HIV","volume":"55","author":"Chen","year":"2022","journal-title":"Blood Rev."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/hiv.13514","article-title":"Enabling CAR T-cell therapies for HIV-positive lymphoma patients\u2014A call for action","volume":"24","author":"Hattenhauer","year":"2023","journal-title":"HIV Med."},{"key":"ref_54","first-page":"e13552","article-title":"The role of chimeric antigen receptor-T cell therapy in the treatment of hematological malignancies: Advantages, trials, and tribulations, and the road ahead","volume":"13","author":"Reddy","year":"2021","journal-title":"Cureus"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s11904-020-00519-w","article-title":"Immunotherapeutics to treat HIV in the central nervous system","volume":"17","author":"Kapoor","year":"2020","journal-title":"Curr. HIV\/AIDS Rep."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Alnefaie, A., Albogami, S., Asiri, Y., Ahmad, T., Alotaibi, S.S., Al-Sanea, M.M., and Althobaiti, H. (2022). Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions. Front. Bioeng. Biotechnol., 10.","DOI":"10.3389\/fbioe.2022.797440"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Kalinichenko, S.V., Ramadan, L., Kruglova, N.A., Lukashina, M.I., Mazurov, D.V., and Shepelev, M.V. (2024). A New Chimeric Antibody against the HIV-1 Fusion Inhibitory Peptide MT-C34 with a High Affinity and Fc-Mediated Cellular Cytotoxicity. Biology, 13.","DOI":"10.3390\/biology13090675"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00281-024-01031-8","article-title":"Cell therapies for viral diseases: A new frontier","volume":"47","author":"Nardo","year":"2025","journal-title":"Semin. Immunopathol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e690","DOI":"10.1016\/S2352-3026(20)30142-3","article-title":"CAR T-cell therapy for cancer and HIV through novel approaches to HIV-associated haematological malignancies","volume":"7","author":"Rust","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Dub\u00e9, K., Kanazawa, J., Patel, H., Louella, M., Sylla, L., Sheehy, J., Dee, L., Taylor, J., Adair, J., and Anthony-Gonda, K. (2022). Ethical and practical considerations for cell and gene therapy toward an HIV cure: Findings from a qualitative in-depth interview study in the United States. BMC Med. Ethics, 23.","DOI":"10.1186\/s12910-022-00780-1"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.ymthe.2024.02.030","article-title":"CD20 CAR T cells safely and reversibly ablate B cell follicles in a non-human primate model of HIV persistence","volume":"32","author":"Bui","year":"2024","journal-title":"Mol. Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/s41586-022-05556-6","article-title":"HIV silencing and cell survival signatures in infected T cell reservoirs","volume":"614","author":"Clark","year":"2023","journal-title":"Nature"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Davey, B.C., Pampusch, M.S., Cartwright, E.K., Abdelaal, H.M., Rakasz, E.G., Rendahl, A., Berger, E.A., and Skinner, P.J. (2022). Development of an anti-CAR antibody response in SIV-infected rhesus macaques treated with CD4-MBL CAR\/CXCR5 T cells. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1032537"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e169309","DOI":"10.1172\/JCI169309","article-title":"Anti\u2013PD-1 chimeric antigen receptor T cells efficiently target SIV-infected CD4+ T cells in germinal centers","volume":"134","author":"Eichholz","year":"2024","journal-title":"J. Clin. Investig."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"103350","DOI":"10.1016\/j.xpro.2024.103350","article-title":"STAR Protocols","volume":"5","author":"Gao","year":"2024","journal-title":"STAR Protoc."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Jiang, Z., Liang, H., Pan, H., Liang, Y., Wang, H., Yang, X., Lu, P., Zhang, X., Yang, J., and Zhang, D. (2021). HIV-1-Specific CAR-T Cells With Cell-Intrinsic PD-1 Checkpoint Blockade Enhance Anti-HIV Efficacy in vivo. Front. Microbiol., 12.","DOI":"10.3389\/fmicb.2021.684016"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.virs.2023.01.003","article-title":"Allogeneic gene-edited HIV-specific CAR-T cells secreting PD-1 blocking scFv enhance specific cytotoxic activity against HIV Env+ cells in vivo","volume":"38","author":"Pan","year":"2023","journal-title":"Virol. Sin."},{"key":"ref_68","first-page":"e150211","article-title":"HIV-specific CAR T cells return to the clinic","volume":"135","author":"Peterson","year":"2025","journal-title":"J. Clin. Investig."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e141502","DOI":"10.1172\/jci.insight.141502","article-title":"Stem cell\u2013derived CAR T cells traffic to HIV reservoirs in macaques","volume":"6","author":"Sze","year":"2021","journal-title":"JCI Insight"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.ymthe.2024.02.026","article-title":"Stem cell-derived CAR T cells show greater persistence, trafficking, and viral control compared to ex vivo transduced CAR T cells","volume":"32","author":"Carrillo","year":"2024","journal-title":"Mol. Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e185489","DOI":"10.1172\/JCI185489","article-title":"Rapamycin enhances CAR-T control of HIV replication and reservoir elimination in vivo","volume":"135","author":"Mu","year":"2025","journal-title":"J. Clin. Investig."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Zhen, A., Carrillo, M.A., Mu, W., Rezek, V., Martin, H., Hamid, P., Chen, I.S.Y., Yang, O.O., Zack, J.A., and Kitchen, S.G. (2021). Robust CAR-T memory formation and function via hematopoietic stem cell delivery. PLoS Pathog., 17.","DOI":"10.1371\/journal.ppat.1009895"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1038\/s41591-020-1039-5","article-title":"Dual CD4-based CAR T cells with distinct costimulatory domains mitigate HIV pathogenesis in vivo","volume":"26","author":"Maldini","year":"2020","journal-title":"Nat. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1021\/acschembio.0c00537","article-title":"A universal CAR-NK cell targeting various epitopes of HIV-1 gp160","volume":"15","author":"Lim","year":"2020","journal-title":"ACS Chem. Biol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00430-020-00692-0","article-title":"Designed Ankyrin Repeat Protein (DARPin) to target chimeric antigen receptor (CAR)-redirected T cells towards CD4+ T cells to reduce the latent HIV+ cell reservoir","volume":"209","author":"Patasic","year":"2020","journal-title":"Med. Microbiol. Immunol."},{"key":"ref_76","first-page":"3053","article-title":"Simultaneous targeting of B-cell malignancies and human immunodeficiency virus with bispecific chimeric antigen receptor T cells","volume":"109","author":"Urak","year":"2024","journal-title":"Haematologica"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"101486","DOI":"10.1016\/j.omtm.2025.101486","article-title":"Anti-HIV-1 HSPC-based gene therapy with safety kill switch to defend against and attack HIV-1 infection","volume":"33","author":"Guo","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e03839-24","DOI":"10.1128\/mbio.03839-24","article-title":"Engineering of CD8+ T cells with an HIV-specific synthetic notch receptor to secrete broadly therapeutic antibodies for combining antiviral humoral and cellular immune responses","volume":"16","author":"Meng","year":"2025","journal-title":"mBio"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"101484","DOI":"10.1016\/j.omtm.2025.101484","article-title":"Enhancing titers of therapeutic lentiviral vectors using PKC agonists","volume":"33","author":"Clarkson","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Rothemejer, F.H., Lauritsen, N.P., S\u00f8gaard, O.S., and Tolstrup, M. (2023). Strategies for enhancing CAR T cell expansion and persistence in HIV infection. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1253395"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.omtm.2020.09.014","article-title":"Conditionally replicating vectors mobilize chimeric antigen receptors against HIV","volume":"19","author":"Urak","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Urak, R., Gittins, B., Soemardy, C., Grepo, N., Goldberg, L., Maker, M., Shevchenko, G., Davis, A., Li, S., and Scott, T. (2023). Evaluation of the elements of short hairpin RNAs in developing shRNA-containing CAR T cells. Cancers, 15.","DOI":"10.3390\/cancers15102848"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.chom.2021.01.006","article-title":"HIV-infected macrophages resist efficient NK cell-mediated killing while preserving inflammatory cytokine responses","volume":"29","author":"Clayton","year":"2021","journal-title":"Cell Host Microbe"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1089\/aid.2020.0163","article-title":"Real-time killing assays to assess the potency of a new anti-simian immunodeficiency virus chimeric antigen receptor T cell","volume":"36","author":"Haeseleer","year":"2020","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e20220666","DOI":"10.1084\/jem.20220666","article-title":"RELA tunes innate-like interferon I\/III responses in human T cells","volume":"220","author":"Jeremiah","year":"2023","journal-title":"J. Exp. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"145715","DOI":"10.1016\/j.ijbiomac.2025.145715","article-title":"A novel FITC-chimeric antigen receptor-T cell targeting HIV-1-infected cells with FITC-conjugated antibodies for enhanced cytotoxicity","volume":"319","author":"Mi","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Tao, L., Farooq, M.A., Gao, Y., Zhang, L., Niu, C., Ajmal, I., Zhou, Y., He, C., Zhao, G., and Yao, J. (2020). CD19-CAR-T cells bearing a KIR\/PD-1-based inhibitory CAR eradicate CD19\u207aHLA-C1 malignant B cells while sparing CD19\u207aHLA-C1\u207a healthy B cells. Cancers, 12.","DOI":"10.3390\/cancers12092612"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Zenere, G., Wu, C., Midkiff, C.C., Johnson, N.M., Grice, C.P., Wimley, W.C., Kaur, A., and E Braun, S. (2024). Extracellular domain, hinge, and transmembrane determinants affecting surface CD4 expression of a novel anti-HIV chimeric antigen receptor (CAR) construct. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0293990"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.omtm.2021.06.008","article-title":"Immune inactivation of anti-simian immunodeficiency virus chimeric antigen receptor T cells in rhesus macaques","volume":"22","author":"Haeseleer","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Iwamoto, N., Wagers, I.D., Patel, B., Song, K., Mason, R., Bolivar, S., Bergamaschi, C., Roederer, M., Pavlakis, G.N., and Berger, E. (2021). Evaluation of chimeric antigen receptor T cell therapy in non-human primates infected with SHIV or SIV. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0248973"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Kranz, E., Kuhlmann, C.J., Chan, J., Kim, P.Y., Chen, I.S.Y., and Kamata, M. (2022). Efficient derivation of chimeric antigen receptor-modified TSCM cells. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.877682"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Pampusch, M.S., Sevcik, E.N., Quinn, Z.E., Davey, B.C., Berg, J.M., Gorrell-Brown, I., Abdelaal, H.M., Rakasz, E.G., Rendahl, A., and Skinner, P.J. (2023). Assessment of anti-CD20 antibody pre-treatment for augmentation of CAR-T cell therapy in SIV-infected rhesus macaques. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1101446"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"100073","DOI":"10.1016\/j.jve.2022.100073","article-title":"Advances in HIV-1-specific chimeric antigen receptor cells to target the HIV-1 reservoir","volume":"8","author":"Choudhary","year":"2022","journal-title":"J. Virus Erad."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"109207","DOI":"10.1016\/j.celrep.2021.109207","article-title":"Targeted delivery of CRISPR-Cas9 and transgenes enables complex immune cell engineering","volume":"35","author":"Hamilton","year":"2021","journal-title":"Cell Rep."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Zhou, Y., Jadlowsky, J., Baiduc, C., Klattenhoff, A.W., Chen, Z., Bennett, A.D., Pumphrey, N.J., Jakobsen, B.K., and Riley, J.L. (2023). Chimeric antigen receptors enable superior control of HIV replication by rapidly killing infected cells. PLoS Pathog., 19.","DOI":"10.1371\/journal.ppat.1011853"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e21886","DOI":"10.1016\/j.heliyon.2023.e21886","article-title":"Enhanced infection efficiency and cytotoxicity mediated by vpx-containing lentivirus in chimeric antigen receptor macrophage (CAR-M)","volume":"9","author":"Gao","year":"2023","journal-title":"Heliyon"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Padurariu-Covit, M.-D., Chiscop, I., Gutu, C., Arbune, A.-A., Niculet, E., and Arbune, M. (2025). Retrospective analysis of HIV-associated lymphomas: Insights from a single Romanian center over 15 years. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1569433"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.21037\/atm-20-4363","article-title":"Efficacy and safety of CD19 chimeric antigen receptor T cells in the treatment of 11 patients with relapsed\/refractory B-cell lymphoma: A single-center study","volume":"8","author":"Huang","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1186\/s13256-022-03636-9","article-title":"Five-year remission without disease progression in a patient with relapsed\/refractory multiple myeloma with extramedullary disease treated with LCAR-B38M chimeric antigen receptor T cells in the LEGEND-2 study: A case report","volume":"16","author":"Wang","year":"2022","journal-title":"J. Med. Case Rep."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Zhong, G., Zhang, X., Guo, Z., Gao, Y., Zhao, B., Liu, X., Chen, L., Qiao, J., Yu, C., and Wang, L. (2024). Complete remission of advanced pancreatic cancer induced by claudin18.2-targeted CAR-T cell therapy: A case report. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1325860"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Yang, L., Wu, M., Yang, H., Sun, X., Xing, L., Liu, D., Xing, L., and Yu, J. (2024). Case report: Bridging radiation therapy before chimeric antigen receptor T-cell therapy induces sustained remission in patients with relapsed\/refractory double-expressor diffuse large B-cell lymphoma with localized compressive symptoms. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1441404"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e735","DOI":"10.1097\/HS9.0000000000000735","article-title":"Sustained remission of relapsed diffuse large B-cell lymphoma after safe administration of CD19-directed CAR T-cells in a patient with chronic intestinal and pulmonal GvHD","volume":"6","author":"Kutsch","year":"2022","journal-title":"HemaSphere"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"651","DOI":"10.4269\/ajtmh.21-0246","article-title":"Case Report: Refractory Cryptosporidiosis after CAR T-Cell Therapy for Lymphoma","volume":"105","author":"Trottier","year":"2021","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/cyto.a.24825","article-title":"The challenge of standardizing CAR-T cell monitoring: A comparison of two flow-cytometry methods and correlation with qPCR technique","volume":"105","year":"2024","journal-title":"Cytom. A"},{"key":"ref_105","unstructured":"Alali, A., Ferreira, C.B., Folorunso, O.S., Alquethamy, S.F., Al-Yahya, S., Alanazi, M., Alamer, O.M., Al-Harbi, H.M., and Mahfouz, M. (2022). Genetic engineering strategies for HIV cure: Advances in CAR-T cell therapy. Int. J. Mol. Sci., 23."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"ofad633","DOI":"10.1093\/ofid\/ofad633","article-title":"False-Positive Human Immunodeficiency Virus Nucleic Acid Amplification Test After Chimeric Antigen Receptor T-Cell Therapy With Ciltacabtagene Autoleucel","volume":"11","author":"Keri","year":"2023","journal-title":"Open Forum Infect. Dis."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1093\/infdis\/jiab605","article-title":"False-positive human immunodeficiency virus test results in patients receiving lentivirus-based chimeric antigen receptor T-cell therapy: Case report, review of the literature, and proposed recommendations","volume":"225","author":"Villalba","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Yoon, S.E., Huh, K., Kim, T.Y., Huh, H.J., Kim, S.J., and Kim, W.S. (Case Rep. Cancer Res. Treat., 2025). Detection of HIV RNA after CAR-T Cell Therapy in a Relapsed\/Refractory Diffuse Large B-Cell Lymphoma Patient: Possibility of False Positivity and Clinical Implications, Case Rep. Cancer Res. Treat., ahead of print.","DOI":"10.4143\/crt.2025.491"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Li, K., Zhang, C., Deng, J., Zeng, H., Zhang, Y., Lai, G., Zhong, X., and Xie, B. (2024). Causal Effects of Gut Microbiome on HIV Infection: A Two-Sample Mendelian Randomization Analysis. BMC Infect. Dis., 24.","DOI":"10.1186\/s12879-024-09176-5"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Chou, T.C., Maggirwar, N.S., and Marsden, M.D. (2024). HIV Persistence, Latency, and Cure Approaches: Where Are We Now?. Viruses, 16.","DOI":"10.3390\/v16071163"},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Conway, J.M., Perelson, A.S., and Li, J.Z. (2019). Predictions of Time to HIV Viral Rebound Following ART Suspension That Incorporate Personal Biomarkers. PLoS Comput. Biol., 15.","DOI":"10.1371\/journal.pcbi.1007229"},{"key":"ref_112","unstructured":"European Centre for Disease Prevention and Control (2023). Stigma: Survey of People Living with HIV. Monitoring Implementation of the Dublin Declaration on Partnership to Fight HIV\/AIDS in Europe and Central Asia: 2022 Progress Report."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1634\/theoncologist.2019-0853","article-title":"Inclusive Cancer Care: Rethinking Patients Living with HIV and Cancer","volume":"25","author":"Corrigan","year":"2020","journal-title":"Oncologist"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1182\/blood.2023020703","article-title":"Mitigating inequity: Ethically prioritizing patients for CAR T-cell therapy","volume":"142","author":"Bell","year":"2023","journal-title":"Blood"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/12\/1615\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T09:49:11Z","timestamp":1765792151000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/12\/1615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,14]]},"references-count":114,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["v17121615"],"URL":"https:\/\/doi.org\/10.3390\/v17121615","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,14]]}}}